FDA Approves Subcutaneous Lecanemab for Early Alzheimer's Treatment

Why it matters locally: The approval of at-home administered lecanemab could significantly impact healthcare access for an estimated 130,000 Tennesseans living with Alzheimer's disease, potentially reducing the burden on caregivers and medical facilities across the state.

The Food and Drug Administration (FDA) has granted approval for LEQEMBI IQLIK (lecanemab-irmb), a subcutaneous injection intended for individuals with early Alzheimer's disease. This new formulation allows for administration at home. LEQEMBI IQLIK serves as an anti-amyloid treatment. The approval specifically covers its use as an initiation dose. This marks the first time a treatment for early Alzheimer's disease has received approval for at-home, subcutaneous initiation and maintenance dosing. Patients can administer LEQEMBI IQLIK at home, following initial guidance from healthcare providers. The at-home administration method aims to provide greater convenience for eligible individuals and their caregivers. Physicians will continue to assess patient suitability for this treatment.